InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the full record of transactions filed by Sandler Alan B., Responsable du Développement Mondial, Oncologie. Insider active across 2 companies, notably Zai Lab Ltd. Cumulatively, 6 filings have been recorded. Activity tracked since 1 December 2021. The latest transaction was disclosed on 29 December 2023 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Sandler Alan B.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
10,547 股Common StockSEC:0001140361-24-003530:0
17,021 股@ US$58.7554.6% 占其流量Common StockSEC:0001628280-24-000282:0
22,297 股@ US$37.0045.4% 占其流量Common StockSEC:0001628280-23-028871:0
40,000 股0Common StockSEC:0001214659-22-013305:0
1,060 股0American Depositary SharesSEC:0000899243-22-013696:0
2,075 股@ US$71.23100.0% 占其流量Ordinary SharesSEC:0001567619-21-021622:0
6 条申报中的 6 条
About Sandler Alan B.
Sandler Alan B. is Head of Global Dev., Oncology. He has 6 filings in total, and across the recent filings we track, the most frequent transaction nature is Attribution, with filings dated from 2021-12-03 to 2024-01-23. The listed amounts include EUR 903475.2854080361 for Mirati Therapeutics, Inc. on 2024-01-03, EUR 751515.4981401361 for Mirati Therapeutics, Inc. on 2023-08-10, and EUR 130448.7811680655 for Zai Lab Ltd on 2021-12-03.
